Granules India Limited has filed its monitoring agency report for the quarter ended March 31, 2026, with the National Stock Exchange of India Limited and BSE Limited. The report, issued by M/s. India Ratings & Research Private Limited, covers the utilization of proceeds raised through the company's preferential issue in accordance with Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The preferential issue was conducted between February 10, 2026, and February 23, 2026, comprising 51,28,205 equity shares of face value ₹ 1 each at INR 585 per share and 2,50,00,000 convertible warrants at INR 585 per warrant. The total issue size amounted to INR 1,762.50 Crores. As of March 31, 2026, the company had received INR 665.63 Crores, which included the full subscription amount for equity shares (INR 300.00 Crores) and 25% upfront payment for convertible warrants (INR 365.63 Crores).

The monitoring agency confirmed no deviation from the objects of the issue based on the management undertaking and statutory auditor certificate dated April 23, 2026, issued by S.R. Batliboi & Associates LLP. The proceeds were allocated for funding business operations, including capital expenditure, operating expenses, prepayment of term loans, working capital, vendor payments, and general corporate purposes.

During the quarter ended March 31, 2026, the company utilized INR 218.14 Crores of the proceeds. The utilization included INR 44.21 Crores for salary payments under general corporate purposes and various amounts for capital expenditure, operating expenses, and investments in subsidiaries. The company also made an equity investment of INR 400.00 Crores in M/s Granules Life Sciences Private Limited during the quarter.

The unutilized proceeds of INR 447.48 Crores as of March 31, 2026, have been deployed in fixed deposits with Union Bank of India and maintained in monitoring accounts. Five fixed deposits of INR 10.00 Crores each, maturing on June 25, 2026, yielded returns at 6.80%. Additionally, INR 14.76 Crores remained in the Kotak Bank monitoring account, and INR 382.88 Crores was held with Granules Life Sciences Private Limited.

The monitoring agency noted that all projects are ongoing as per the tentative timelines specified in the offer document, with no delays reported. The company has 18 months from the issue date for warrant holders to exercise their conversion option, with the balance 75% of warrant value (INR 438.75 per warrant) to be received upon conversion.

Granules India Limited has announced the record date for its final dividend distribution for the financial year ended March 31, 2026. The pharmaceutical company communicated this important corporate action to stock exchanges on April 29, 2026.

Record Date Details

The company has set the following parameters for its dividend distribution:

Regulatory Compliance

The announcement was made in strict adherence to regulatory requirements under Regulation 42 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates companies to inform stock exchanges about record dates for various corporate actions, including dividend distributions.

The communication was signed by Chaitanya Tummala, Company Secretary & Compliance Officer, and was digitally authenticated on April 29, 2026. The formal intimation was sent to both National Stock Exchange India Limited and BSE Limited, where the company's shares are listed.

Shareholder Implications

Shareholders who hold Granules India Limited shares on the record date of July 30, 2026 will be eligible to receive the final dividend for FY26. This record date serves as the cut-off for determining dividend entitlement, ensuring that only registered shareholders as of this date will receive the dividend payment.

The company's registered office is located at the 15th Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad, Telangana. Granules India Limited operates under CIN: L24110TG1991PLC012471 and maintains its corporate communication through official channels as required by regulatory frameworks.